This article is an erratum on:
Exploring HMMR as a therapeutic frontier in breast cancer treatment, its interaction with various cell cycle genes, and targeting its overexpression through specific inhibitors
Frontiers Production Officeby Shabir A, Qayoom H, Haq BU, Abo Mansoor A, Abdelrahim A, Ahmad I, Almilabairy A, Ahmad F and Mir MA (2024). Front. Pharmacol. 15:1361424. doi: 10.3389/fphar.2024.1361424
Due to a production error, there was an error in Affiliation 5. Instead of “Respiratory Care Department, College of Applied Sciences Almaarefa University, Abha, Saudi Arabia,” it should read “Respiratory Care Department, College of Applied Sciences Almaarefa University, Diriya, Riyadh, Saudi Arabia.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: HMMR, breast cancer, biomarkers, Cdk1, AURKA, Tpx2, mTOR, MD simulation
Citation: Frontiers Production Office (2024) Erratum: Exploring HMMR as a therapeutic frontier in breast cancer treatment, its interaction with various cell cycle genes, and targeting its overexpression through specific inhibitors. Front. Pharmacol. 15:1443537. doi: 10.3389/fphar.2024.1443537
Received: 04 June 2024; Accepted: 04 June 2024;
Published: 21 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org